| 6J1L | date | ![]() |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| authors | |||||||||||||||
| compound | source | ||||||||||||||
| symmetry |
| ||||||||||||||
| crystal cell |
| ||||||||||||||
| method | X-Ray Diffraction | resolution | |||||||||||||
| ligand | B6L | enzyme |
| ||||||||||||
| Gene Ontology |
| ||||||||||||||
| Primary reference | Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORgamma Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer., Zhang Y, Wu X, Xue X, Li C, Wang J, Wang R, Zhang C, Wang C, Shi Y, Zou L, Li Q, Huang Z, Hao X, Loomes K, Wu D, Chen HW, Xu J, Xu Y, J Med Chem. 2019 Apr 22. doi: 10.1021/acs.jmedchem.9b00327. PMID:30964293 | ||||||||||||||
| Data retrieval |
![]() |
| View 6J1L in 3D |
Proteopedia, because life has more than 2D. |
| Structure-derived information |
| Sequence-derived information |
|
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |